MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Gastrointestinal symptoms predict cognitive decline in Parkinson’s Disease

A. Gonçalves, A. Mendes, N. Vila-Chã, I. Moreira, S. Cavaco (Porto, Portugal)

Meeting: 2019 International Congress

Abstract Number: 1565

Keywords: Cognitive dysfunction, Gastrointestinal problemsm(also see autonomic dysfunction)

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Motor Symptoms

Session Time: 1:15pm-2:45pm

Location: Agora 3 West, Level 3

Objective: To explore the predictive value of non-motor symptoms on the cognitive decline of patients with Parkinson’s disease (PD) in a three-year follow up.

Background: Patients with PD are at increased risk of cognitive decline. It is clinically important to identify predictors of cognitive decline. The existing evidence suggests that non-motor symptoms of PD may be critical determinants of PD prognosis. Non-motor symptoms often occur in clusters, which may reflect different phenotypes of the disease.

Method: Sixty-two consecutive patients with PD (60% men; mean age=68±11; education=7±4; disease duration=8±6; levodopa equivalent dose=784mg±583; UPDRS-III Off=31±11 and On=20±8) performed the Dementia Rating Scale-2 (DRS-2) and answered the Non Motor Symptoms Scale (NMSS). Participants were evaluated at baseline and after an approximate 3-year period (mean= 1092 days±64). The 5th percentile of demographically adjusted norms (adjusted for age and education based on normative data) was used to identify cognitive impairment on the DRS-2 total score. Cognitive decline at follow up was defined as a DRS-2 total adjusted score decline greater than 0.5. Chi-square, Mann-Whitney, and Multiple Logistic Regressions were applied for data analyses.

Results: Seventeen patients (27%) had cognitive impairment at baseline and 35 patients (56%) showed cognitive decline at follow-up. Cognitive decline was related with older age (p=0.016), longer disease duration (p=0.020), higher levodopa equivalent dose (p=0.022), and more non-motor symptoms on NMSS total score (p=0.024) in the first evaluation. No significant associations (p>0.05) were found with sex, education, age at disease onset, UPDRS-III OFF and ON, or cognitive impairment at baseline. Regarding the 9 NMSS domains, patients with cognitive decline at follow up had more attention/memory (domain 5; p=0.012) and gastrointestinal tract (domain 6; p=0.009) complaints at baseline. Gastrointestinal symptoms (adj odds=1.234, p=0.013) and specifically constipation (adj odds=1.244, p=0.041) remained statistically associated with cognitive decline even when age, disease duration and levodopa equivalent dose were taken into account.

Conclusion: The study results revealed that gastrointestinal symptoms are significant predictors of future cognitive decline in PD. These findings may provide additional support to the concept of “gut-brain axis” in PD.

To cite this abstract in AMA style:

A. Gonçalves, A. Mendes, N. Vila-Chã, I. Moreira, S. Cavaco. Gastrointestinal symptoms predict cognitive decline in Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/gastrointestinal-symptoms-predict-cognitive-decline-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/gastrointestinal-symptoms-predict-cognitive-decline-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley